Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Accured Expenses (2020 - 2024)

Immuneering (IMRX) has 5 years of Change in Accured Expenses data on record, last reported at -$718.0 in Q4 2024.

  • For Q4 2024, Change in Accured Expenses fell 100.05% year-over-year to -$718.0; the TTM value through Dec 2024 reached -$200831.0, down 183.69%, while the annual FY2024 figure was -$200831.0, 183.69% down from the prior year.
  • Change in Accured Expenses reached -$718.0 in Q4 2024 per IMRX's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.0 million in Q2 2021 and bottomed at -$1.8 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is $224433.1, with a median of $69982.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 2432.12% in 2022, then plummeted 3712.3% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$257046.0 in 2020, then skyrocketed by 314.39% to $551080.0 in 2021, then dropped by 21.97% to $430006.0 in 2022, then soared by 240.5% to $1.5 million in 2023, then plummeted by 100.05% to -$718.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$718.0 in Q4 2024, $1.2 million in Q3 2024, and -$1.2 million in Q2 2024.